The current medical aesthetic market is worth $52,405 million for both service and product revenue, which over the next five years will grow at 5.5 percent CAGR and is expected to hit $69,786 million in 2021, according to an analysis. The invasive aesthetic procedures are set to grow at a CAGR of 4.3%, while non-invasive procedures will grow at a CAGR of 4.5 percent over the coming five years. Cosmetic surgery products generated $7,824.0 million in 2015 and have the potential to reach $13,934.0 million in 2021.
Nonsurgical treatments lead the way across the globe and are broadly classified into three major categories: injectable products, energy-based devices, and active cosmetics. Injectable products include neurotoxins such as Botox and dermal fillers such as Restylane and they have the largest market share. These are followed by energy-based devices such as lasers, radio frequency, and intense pulsed light (IPL). Cosmeceuticals include skin care, eye care, skin lightening, and scar care products.
The North American market accounts for about 45 percent of the global market. However, the dominance of the U.S. is shifting towards Asia, particularly in the energy- based devices segment. Asia is regarded as the next frontier and the number of physicians and clinics in China and India has been steadily rising, along with medical tourism in the region. In the injectables and devices category, the E.U. occupies the second position behind the U.S. Brazil continues to be a strong market for aesthetics and cosmetic procedures. The Russian market is also experiencing fast growth compared to many E.U. countries and the Russian market is particularly strong for devices and topicals.
Aesthetic practitioners have now the choice of new instrumentations such as soft and bendable needles, blunt-tip cannulas, and injector pens for minimally invasive procedures. Recent years have seen wide acceptance by consumers for microneedle treatments administered via handheld guns, for restoring skin with vitamins, amino acids and hyaluronic acid. Consumer aesthetic products such as “micro- botox” and “bro-tox” are experiencing a steady growth. Adipose derived stem cells (ADSC) have gained acceptance for rejuvenating face and breasts, and stem cells from green apple, lilac and alpine roses are now being used as ingredients in topical cosmetics.
Another growth market is for body shaping procedures that involves reduction of fat, cellulite, skin laxity, and vein removal. An injectable drug ATX-101 (deoxycholic acid), currently in clinical trials is most likely to become a game changer in body contouring segment in the near future. On July 10, 2014, the FDA accepted the filing of New Drug Application (NDA) for this drug by Kythera Biopharmaceuticals. Plug-in at-home devices for treating sun damage, hair removal, skin discoloration, acne, hair growth, skin texture, microdermabrasion, and cellulite continue to expand particularly in developed markets. As a new innovation, the aesthetic market is expected to witness the launch of transepidermal drug delivery technologies for facilitating topical treatments.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
